Malaria Information and Prophylaxis, by Country [T]

Print
Related Pages

The information presented in this table is consistent 1 with the information in the CDC Health Information for International Travel (the “Yellow Book”).

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Malaria Information and Prophylaxis by Country
Country Areas with Malaria Drug Resistance2 Malaria Species3 Recommended Chemoprophylaxis4 Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries
Taiwan None Not Applicable Not Applicable Not Applicable
Tajikistan No indigenous cases reported since 2014. Previously, chloroquine Previously, P. vivax 90% and

P. falciparum 10%

 None (mosquito avoidance only).6
Tanzania All areas at altitudes < 1,800 m (5,906 ft) Chloroquine Primarily P. falciparum. Less commonly, P. malariae or P. ovale;

P. vivax rare

 Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5 Altitude of city(ies) of travel

Altitude information
Thailand Primarily in provinces that border Burma (Myanmar), Cambodia (few cases in Buriram), and Malaysia (few cases in Satun), and the provinces of Surat Thani, Ubon Ratchathani, and Phitsanulok, especially the rural forest and forest fringe areas of these provinces. Rare to few cases in other parts of Thailand, including the cities of Bangkok, Chiang Mai, and Chiang Rai, and the islands of Koh Phangan, Koh Samui, and Phuket. None in the islands of Krabi Province (Koh Phi Phi, Koh Yao Noi, Koh Yao Yai, and Ko Lanta) and Pattaya City Chloroquine and Mefloquine P. vivax 80%; P. falciparum <20%; P. knowlesi,7 P. malariae and P. ovale rare.

 

 Provinces that border Burma (Myanmar), Cambodia (except Buriram),  and Malaysia (except Satun), and the provinces of Surat Thani, Ubon Ratchathani, and Phitsanulok:

Atovaquone-proguanil doxycycline, or tafenoquine5.

Other areas with malaria:
None (mosquito avoidance only).6

 Map of provinces of Thailand to determine if a city is within a certain district
Timor-Leste (East Timor) Rare cases; outbreak in Indonesia border area in mid-2020. Chloroquine Previously, P. falciparum 50%,

P. vivax 50%,

P. ovale <1%,

P. malariae <1%

 None (mosquito avoidance only).6
Togo All Chloroquine Primarily P. falciparum. Less commonly, P. malariae, P. ovale, or P. vivax. Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Tokelau (New Zealand) None Not Applicable Not Applicable Not Applicable
Tonga None Not Applicable Not Applicable Not Applicable
Trinidad and Tobago None Not Applicable Not Applicable Not Applicable
Tunisia None Not Applicable Not Applicable Not Applicable
Turkey None Not Applicable Not Applicable Not Applicable
Turkmenistan None Not Applicable Not Applicable Not Applicable
Turks and Caicos Islands (U.K.) None Not Applicable Not Applicable Not Applicable
Tuvalu None Not Applicable Not Applicable Not Applicable

1. Factors that affect local malaria transmission patterns can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection. Information in these tables is updated regularly.
2.  Refers to P. falciparum malaria unless otherwise noted.
3. Estimates of malaria species are based on best available data from multiple sources. Where proportions are not available, the primary species and less common species are identified.
4. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
5. Primaquine and tafenoquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Before prescribing primaquine or tafenoquine, patients must be screened for G6PD deficiency using a quantitative test.
6. Mosquito avoidance includes applying topical mosquito repellant, sleeping under an insecticide treated bed net, and wearing protective clothing (e.g., long pants and socks, long sleeve shirt). For additional details on mosquito avoidance, see: https://www.cdc.gov/malaria/travelers/index.html
7. P. knowlesi is a malaria species with a simian host (macaque). Human cases have been reported from most countries in Southeast Asia and are associated with activities in forest or forest-fringe areas. This species of malaria has no known resistance to antimalarials.